unlearn
Creates AI digital twins to accelerate clinical drug trials.
Company facts
- Founded
- 2017
- Employees
- 68
- Headquarters
- United States
- CEO
- Steven Herne
- Type
- Private
- Funding
- Series C · $50M · 2024
About
Unlearn.AI pioneers AI-driven solutions for clinical trials, transforming how medical research is conducted. The company leverages advanced artificial intelligence and digital twin technology to create dynamic, predictive models of patients involved in clinical studies, resulting in efficient, smaller trials that maintain scientific robustness. This innovative approach aims to eliminate the traditional trial-and-error method prevalent in medicine today and to enhance the reliability of clinical outcomes through precise predictions. Founded in 2017 and headquartered in San Francisco, California, Unlearn.AI focuses on accelerating the drug development process, particularly in complex therapeutic areas such as neuroscience and metabolic diseases. The firm’s flagship offering, the Unlearn Platform, allows researchers to visualize potential clinical outcomes for subgroups, aiding in informed decision-making during trials. The digital twin technology not only predicts various health outcomes for patients but also optimizes trial designs, enhances clinical insights, and ultimately aims to deliver better health solutions for patients with various medical conditions.